Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23

Rhea-AI Summary

Codexis, a prominent enzyme engineering company, announced it will report its financial results for Q4 and fiscal year 2022 on February 23, 2023, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results and provide a business update.

Participants can access the live webcast on Codexis' Investor Relations website, where it will be archived for 90 days. The call can be accessed by dialing the provided numbers with the conference ID #13735352 for live participation and access ID #13726635 for replays.

Positive

• Upcoming financial results report for Q4 and fiscal year 2022 may provide insights into company performance.
• Scheduled conference call may increase investor engagement and transparency.

Negative

• None.

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing (877) 705-2976 (domestic) or (201) 689-8798 (international), conference ID #13735352. A replay of the call will be available for 48 hours by dialing (877) 660-6853 (domestic) or (201) 612-7415 (international), access ID #13726635.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver^® platform to discover and develop novel, high performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of small molecule pharmaceuticals, in RNA and DNA synthesis and the creation of next generation life science tools, and as gene therapies and oral enzyme therapies. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved return on capital in manufacturing, improved sensitivity in genomic and diagnostic applications, and more efficacious therapeutics. For more information, visit www.codexis.com.

Investor Relations Contact:

Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902
Codexis@argotpartners.com

FAQ

When will Codexis report its Q4 and fiscal year 2022 results?

Codexis will report its Q4 and fiscal year 2022 results on February 23, 2023.

What time is the Codexis conference call scheduled for?

The conference call is scheduled for 4:30 p.m. Eastern Time on February 23, 2023.

How can I access the Codexis conference call?

You can access the call by dialing (877) 705-2976 for domestic or (201) 689-8798 for international participants.

Where can I find Codexis' financial results after the announcement?

The financial results will be archived on Codexis' Investor Relations website for 90 days.